KR20190020838A - 항-robo4 항체 - Google Patents

항-robo4 항체 Download PDF

Info

Publication number
KR20190020838A
KR20190020838A KR1020197004552A KR20197004552A KR20190020838A KR 20190020838 A KR20190020838 A KR 20190020838A KR 1020197004552 A KR1020197004552 A KR 1020197004552A KR 20197004552 A KR20197004552 A KR 20197004552A KR 20190020838 A KR20190020838 A KR 20190020838A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197004552A
Other languages
English (en)
Korean (ko)
Inventor
요시타카 이스미
도시유키 사토
준 하세가와
다츠야 이노우에
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2012103929A external-priority patent/JP2013230115A/ja
Priority claimed from JP2013011042A external-priority patent/JP2014141434A/ja
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20190020838A publication Critical patent/KR20190020838A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
KR1020197004552A 2012-04-27 2013-04-26 항-robo4 항체 Ceased KR20190020838A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2012-103929 2012-04-27
JP2012103929A JP2013230115A (ja) 2012-04-27 2012-04-27 抗ｒｏｂｏ４抗体
JP2013011042A JP2014141434A (ja) 2013-01-24 2013-01-24 抗ｒｏｂｏ４抗体
JPJP-P-2013-011042 2013-01-24
PCT/IB2013/053312 WO2013160879A1 (en) 2012-04-27 2013-04-26 Anti-robo4-antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029492A Division KR101950898B1 (ko) 2012-04-27 2013-04-26 항-robo4 항체

Publications (1)

Publication Number Publication Date
KR20190020838A true KR20190020838A (ko) 2019-03-04

Family

ID=48670623

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197004552A Ceased KR20190020838A (ko) 2012-04-27 2013-04-26 항-robo4 항체
KR1020147029492A Expired - Fee Related KR101950898B1 (ko) 2012-04-27 2013-04-26 항-robo4 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147029492A Expired - Fee Related KR101950898B1 (ko) 2012-04-27 2013-04-26 항-robo4 항체

Country Status (22)

Country Link
US (2) US9683040B2 (https=)
EP (1) EP2841457B1 (https=)
JP (2) JP5897205B2 (https=)
KR (2) KR20190020838A (https=)
CN (1) CN104768973B (https=)
AU (1) AU2013254313B2 (https=)
BR (1) BR112014026649A2 (https=)
CA (1) CA2868074A1 (https=)
CO (1) CO7111295A2 (https=)
DK (1) DK2841457T3 (https=)
ES (1) ES2733434T3 (https=)
IN (1) IN2014DN07799A (https=)
MX (1) MX356749B (https=)
MY (1) MY166821A (https=)
NZ (1) NZ629291A (https=)
PH (1) PH12014502382B1 (https=)
PL (1) PL2841457T3 (https=)
RU (1) RU2682451C2 (https=)
SG (1) SG11201405718QA (https=)
TW (1) TWI606065B (https=)
WO (1) WO2013160879A1 (https=)
ZA (1) ZA201406235B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356749B (es) * 2012-04-27 2018-06-12 Daiichi Sankyo Co Ltd Anticuerpo anti-homologo 4 de roundabout (robo4).
TWI909341B (zh) 2015-09-24 2025-12-21 日商第一三共股份有限公司 抗garp抗體及其製造方法及用途
WO2018070390A1 (ja) * 2016-10-12 2018-04-19 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
KR20210070643A (ko) 2019-12-05 2021-06-15 김명배 자체 발전 웨어러블 다리
WO2023156437A1 (en) 2022-02-16 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
WO2025045139A1 (zh) * 2023-08-31 2025-03-06 舒泰神（北京）生物制药股份有限公司 特异性识别robo2的抗体及其应用
CN117384290B (zh) * 2023-12-11 2024-04-09 苏州因特药物研发有限公司 人源robo1结合分子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US7498034B2 (en) * 2000-11-06 2009-03-03 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
JP4583638B2 (ja) 2001-03-15 2010-11-17 独立行政法人科学技術振興機構 アセチルリジン認識モノクローナル抗体及びその製造方法
WO2004003163A2 (en) 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
US20060099143A1 (en) * 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
ES2273202T3 (es) 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
KR20090089462A (ko) 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
AR065271A1 (es) 2007-02-09 2009-05-27 Genentech Inc Anticuerpos anti-robo4 y sus usos
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
MX356749B (es) * 2012-04-27 2018-06-12 Daiichi Sankyo Co Ltd Anticuerpo anti-homologo 4 de roundabout (robo4).

Also Published As

Publication number Publication date
JP2015515490A (ja) 2015-05-28
BR112014026649A2 (pt) 2017-07-18
JP5897205B2 (ja) 2016-03-30
PH12014502382A1 (en) 2015-01-12
US20160108120A1 (en) 2016-04-21
TW201348257A (zh) 2013-12-01
PH12014502382B1 (en) 2015-01-12
KR101950898B1 (ko) 2019-02-22
EP2841457B1 (en) 2019-04-24
US9562096B2 (en) 2017-02-07
KR20150008074A (ko) 2015-01-21
WO2013160879A1 (en) 2013-10-31
MX2014012351A (es) 2015-01-12
MY166821A (en) 2018-07-23
MX356749B (es) 2018-06-12
TWI606065B (zh) 2017-11-21
ES2733434T3 (es) 2019-11-29
ZA201406235B (en) 2016-07-27
JP2016175893A (ja) 2016-10-06
IN2014DN07799A (https=) 2015-05-15
RU2682451C2 (ru) 2019-03-19
DK2841457T3 (da) 2019-07-22
PL2841457T3 (pl) 2019-09-30
AU2013254313B2 (en) 2017-03-30
CN104768973B (zh) 2019-01-22
US20150098945A1 (en) 2015-04-09
CN104768973A (zh) 2015-07-08
HK1207093A1 (en) 2016-01-22
AU2013254313A1 (en) 2014-09-18
EP2841457A1 (en) 2015-03-04
US9683040B2 (en) 2017-06-20
RU2014147616A (ru) 2016-06-20
NZ629291A (en) 2016-09-30
CO7111295A2 (es) 2014-11-10
CA2868074A1 (en) 2013-10-31
JP6267733B2 (ja) 2018-01-24
SG11201405718QA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
CN107207604B (zh) 抗alk2抗体
KR102724790B1 (ko) 항 cd147 항체
KR101950898B1 (ko) 항-robo4 항체
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
KR20160066024A (ko) 항 fgfr2 항체와 타제의 조합
AU2015300037B2 (en) Anti-Orai1 antibody
KR102538723B1 (ko) 자기 면역 질환 치료용 항체
US20250122283A1 (en) Composition for cytotoxic t cell depletion
RU2785293C2 (ru) Антитело против cd147
RU2781148C2 (ru) Антитело для лечения аутоиммунных заболеваний
KR102686311B1 (ko) Pd-1/pd-l1을 표적으로 하는 저해제와 cox-2 저해제의 병용
HK40026035A (en) Composition for cytotoxic t cell depletion
HK1207093B (en) Anti-robo4-antibody

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190215

Application number text: 1020147029492

Filing date: 20141021

A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190218

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20190218

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190618

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191112

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190618

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I